AzTrials
AzTrials

Metabolic Acidosis; Critically Ill Patients; Organ DysfunctionNCT04953013

Risk Potential for Organ Dysfunction Associated With Sodium Bicarbonate Therapy (SBT) in Critically Ill Patients

An observational study of Metabolic Acidosis; Critically Ill Patients; Organ Dysfunction, run by Peking University Third Hospital at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aimed to investigate whether hemodynamic status before SBT contributed to the effect of sodium bicarbonate infusion on the risk of neonatal organ dysfunction and mortality in critically ill patients with early metabolic acidosis in ICU. Read more about this study

Who is it for?
Ages 16 years and older
What is being tested?
sodium bicarbonate
How many people
664 participants
Where
1 siteChina
Study dates
1 Aug 2019to 1 Sep 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: We obtained data from the MIMIC-III. The newest version of MIMIC-III, v. 1.4, integrates 61,532 patients admitted to the ICUs of Beth Israel Deaconess Medical Center in Boston, Massachusetts.

Who may be able to join

  • (1) pH≤7.3; (2) BE≤-8, or HCO3- < 20 mmol/L if BE was missing; and (3) PaCO2< 50 mmHg, or without chronic obstructive pulmonary disease (COPD) in discharge diagnoses if PaCO2 was unavailable.

Who cannot join

  • (1) age 16 or under; (2) diabetes insipidus ; (3) comorbidity of peripheral paralysis; (4) ICU stay over 100 days; (5) SBT was initiated before ICU admission , later than 48 hours after ICU admission or after a record of order for renal replacement therapy (RRT); and (6) death within the first 24 hours after ICU admission.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Critical Care Medicine Department

    Beijing, Beijing Municipality, 100191

Other trials in China

About this study

This study aimed to investigate whether hemodynamic status before SBT contributed to the effect of sodium bicarbonate infusion on the risk of neonatal organ dysfunction and mortality in critically ill patients with early metabolic acidosis in ICU.

Read the detailed description

Study Population We obtained data from the MIMIC-III. The newest version of MIMIC-III, v. 1.4, integrates 61,532 patients admitted to the ICUs of Beth Israel Deaconess Medical Center in Boston, Massachusetts.

Our study included patients with severe metabolic acidosis within 48 hours after ICU admission who fulfilled all of the following criteria: (1) pH≤7.3; (2) BE≤-8, or HCO3- < 20 mmol/L if BE was missing; and (3) PaCO2< 50 mmHg, or without chronic obstructive pulmonary disease (COPD) in discharge diagnoses if PaCO2 was unavailable. The lowest values of pH, BE, and HCO3- and the highest value of PaCO2 were selected when there were multiple measurements. We defined a composite of newly "developed or exacerbated organ dysfunction" (d/eOD) as a net increase in Sequential Organ Failure Assessment (SOFA) score ≥2 of at least one organ within 7 days of ICU admission over the baseline (SOFA score in the first 24 hours). Hemodynamic status during the initial resuscitation was defined as hemodynamic improvement, hemodynamic worsening and unchanged hemodynamics.

Variables Characteristic data of patients were extracted, including age and sex; category of diseases (surgical vs medical), history of comorbidity and whether cardiopulmonary resuscitation (CPR) was experienced; and diagnosis of sepsis, shock and AKI. Supportive interventions such as mechanical ventilation (MV) and RRT were recorded. Fluid balances at 24 hours and 48 hours after ICU admission and the total SB dosage administered within the first 48 hours were extracted. The SOFA score including each component was calculated every 24 hours if data were available. The Simplified Acute Physiology Score II (SAPSII) was calculated within the first 24 hours after ICU admission.

Laboratory variables included pH, actual bicarbonate (AB), base excess (BE), PaO2, PaCO2, hematocrit (Hct), hemoglobin (Hb), lactate concentration and electrolytes such as [Na+], [K+], and [Cl-]. We also calculated the anion gap (AG) by the formula AG=[Na+] + [K+] - [Cl-] - [HCO3-] .

A composite of newly d/eOD within 7 days of ICU admission was used as the primary outcome of this study. The secondary outcome was 28-day mortality.

Statistical Analysis Propensity score matching (PSM) was applied to minimize either selection biases or potential confounders for SBT. Continuous variables are expressed as the mean (standard deviation) or median (upper quantile, lower quantile), and a t-test or the Wilcoxon-test was used to compare the differences between groups. Categorical variables are depicted as the number of groups (the number of percentages), and the chi-squared test or Fisher's exact test was applied.Univariate and multivariat logistic regression and Cox regression were used to evaluate the effectiveness of SBT.

All statistical analyses were performed by R (version 3.6.1). A p value less than 0.05 was indicative of statistical significance.

Being tested
sodium bicarbonate
Medical subject headings
Acidosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • sodium bicarbonateDrug

    Drug exposure

Study groups in NCT04953013
Study groupRoleWhat they receive
sodium bicarbonate groupSodium bicarbonate was initiated within 48 hours after ICU admission.
Receives: Drug: sodium bicarbonate
non-sodium bicarbonate groupPatients were not infused with sodium bicarbonate.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. newly developed or exacerbated organ dysfunction

    We defined a composite of newly "developed or exacerbated organ dysfunction" (d/eOD) as a net increase in Sequential Organ Failure Assessment (SOFA) score ≥2 of at least one organ within 7 days of ICU admission over the baseline (SOFA score in the first 24 hours).

    Measured: The duration of the database covers from June 2001 to October 2012.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jul 2021
  2. Study start1 Aug 2019
  3. Primary completion1 Feb 2020
  4. Study completion1 Sep 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
664 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04953013
Sponsor's protocol ID
LM2020046
Status last verified
Jun 2021
First submitted
29 Jun 2021
Last updated
7 Jul 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Metabolic Acidosis; Critically Ill Patients; Organ Dysfunction, run by Peking University Third Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

newly developed or exacerbated organ dysfunction (time frame: The duration of the database covers from June 2001 to October 2012.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2021; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in